Please login to the form below

Not currently logged in
Email:
Password:

rociletinib

This page shows the latest rociletinib news and features for those working in and with pharma, biotech and healthcare.

FDA okays Clovis' Lynparza rival rucaparib

FDA okays Clovis' Lynparza rival rucaparib

The company has been pummelled in recent months after an FDA advisory panel voted against a quick approval of its lung cancer candidate rociletinib, a decision that eventually prompted the company

Latest news

  • FDA panel says no to quick approval of Clovis' rociletinib FDA panel says no to quick approval of Clovis' rociletinib

    An FDA advisory committee all but dashed any hopes that Clovis Oncology had for quick approval of its lung cancer drug rociletinib yesterday. ... Meanwhile Boehringer has a new EGFR inhibitor called BI 1482694 in the pipeline that could now also reach

  • AZ sets price of new lung cancer drug Tagrisso AZ sets price of new lung cancer drug Tagrisso

    The FDA has asked for more data on the drug - called rociletinib - which could potentially hold up the programme by several months. ... The FDA's problems with the dataset for rociletinib hinge on the number of unconfirmed versus confirmed responses to

  • Boehringer takes third-generation NSCLC drug into pivotal trials Boehringer takes third-generation NSCLC drug into pivotal trials

    chemotherapy. Aside from Boehringer, other companies developing third-generation EGFR inhibitors include Clovis Oncology with twice-daily rociletinib (CO-1686) and AZ with once-daily osimertinib/AZD9291, both of which are ... Clinical data on both

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics